Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...
Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking ...
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...
Eli Lilly sued the Health Resources and Services Administration (HRSA) for allegedly blocking the pharma giant's proposal to ...
The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that ...
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
Congress created the 340B Drug Pricing Program to allow covered entities such ... with pushback from large drugmakers like Eli Lilly and AstraZeneca. In January 2023, the Third Circuit Court of ...
Eli Lilly and Co.’s recent decision to drop development at phase II of PD-1 agonist peresolimab in rheumatoid arthritis (RA) because of an inadequate benefit-risk profile brought further attention to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback